Press Releases
Tofacitinib to be positioned after anti-TNFs say payers based on FDA panel review, May 15, 2012
Oral Small Molecules for RA Face High Price-Sensitivity Hurdles, March 20, 2012
Payers Say Birth Control Mandate Will Increase Premiums, February 17, 2012
Payers Outlook for Lipitor Generic Strategy Not Rosy: Market Share Decline Coming Soon, December 2, 2011
Payers to Pharma: In Rheumatology, Innovations without Outcomes are Irrelevant, November 30, 2011
Real Endpoints Investment in Reimbursement Intelligence, November 15, 2011
Oncology Webinar Recap: High Cost of Cancer Drugs Forces Payors, Oncology Practices to Respond With New Payment Models, November 10, 2011
News and Articles
“Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers” American Health and Drug Benefits, March/April, 2012
“Why Pfizer’s Rheumatoid Arthritis Pill May Not Be A Sure Bet” Forbes, March, 2012
“Pfizer’s Rheumatoid Arthritis Pill: Not A Slam Dunk” Pharmalot, March, 2012
Payer Survey: Current Contraception Benefit Structure and Anticipated Impact of Mandated No-Cost Access for All Members , February, 2012
“What Managed Care Thinks of Pfizer And Its Lipitor Strategy” Forbes, December 2011
“Review of Strategies to Enhance Outcomes for Patients with Type 2 Diabetes: Payers’ Perspective” American Health and Drug Benefits, September/October 2011
“What Do Payers Want in Oncology Diagnostics? Insights From a National Survey of Top Commercial and Medicare Health Plans” American Health and Drug Benefits, August 2011
“Payers expect Provenge sales to stay flat” FiercePharma, August 2011
“Most Insurers Say Provenge Use Will Remain Flat” Pharmalot, August 2011
“Payers Insights Into Future Oncology Management” Oncology Business Review, July 2011
“Differing Views On The Eisai Breast Cancer Med” Pharmalot, July 2011
“NCCN Still Recommends Avastin For Breast Cancer” Pharmalot, July 2011
Publications
Biotechnology Entrepreneurship: From Science to Solutions – Chapter 9 “Roadmap to Reimbursement and Access”